Long Tail Of Brands Pose Challenge For Indian Pharma Growth: PwC Report
This article was originally published in PharmAsia News
Executive Summary
The Indian drug industry may risk losing out if newer methods of drug marketing are not part of their long-term strategies.
You may also be interested in...
In India, GSK Takes A Deep Dive To Launch Revolade, Votrient At 75% Price Cut
MUMBAI - Industry analysts in India often credit GlaxoSmithKline Pharmaceuticals Ltd. for the tailor-made localized approach it takes to market products and price them in a way to suit patients who pay for medical costs largely out-of-pocket
Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar
MUMBAI - Becoming too big may have resulted in operational inefficiencies and deteriorating R&D output for global drug makers, but getting bigger may be a successful formula for branded generics businesses in emerging markets
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.